Your iron causes all disease thesis not supported.
Quoted message said:Seems like 'they' have found a comparable .. pharmaceutical .. or two to mimic
the effects of the natural .. phytic acid ..?Oncologist. 2004;9 Suppl 4:38-47. Related Articles, Links
Toward new horizons: the future of bisphosphonate therapy.
Lipton A.
Penn State University, College of Medicine, Milton S. Hershey Medical Center,
500 University Drive, Hershey, Pennsylvania 17033, USA. [email hidden]Bisphosphonate therapy has become a standard of care for patients with
malignant bone disease. In addition, preclinical and preliminary clinical data
suggest that bisphosphonates may prevent cancer-treatment-induced bone loss
(CTIBL) and the development of malignant bone disease in patients with
early-stage cancer. Patients who receive adjuvant hormonal therapy for breast
cancer or androgen-deprivation therapy for prostate cancer are at an especially
high risk for CTIBL because of reduced estrogenic signaling. Oral clodronate
(Bonefos((R)); Anthra Pharmaceuticals; Princeton, NJ), oral risedronate
(Actonel((R)); Proctor and Gamble Pharmaceuticals, Inc.; Cincinnati, OH), and
i.v. zoledronic acid (Zometa((R)); Novartis Pharmaceuticals Corp.; East
Hanover, NJ) have all demonstrated promise in preventing CTIBL in patients
receiving hormonal therapy for breast cancer. Zoledronic acid has demonstrated
efficacy with the longest between-treatment interval (3-6 months) and is
currently being investigated in the Zometa((R))/Femara((R)) Adjuvant Synergy
Trials (Z-FAST and ZO-FAST in the United States and Europe, respectively). In
patients receiving androgen-deprivation therapy for prostate cancer, i.v.
pamidronate (Aredia((R)); Novartis Pharmaceuticals Corp.) and i.v. zoledronic
acid both have demonstrated significant benefits over placebo, but only
zoledronic acid produced significant increases in bone mineral density compared
with baseline values. Additionally, bisphosphonates have demonstrated antitumor
activities in preclinical models, and clinical trials with oral clodronate
suggest that bisphosphonates might prevent or delay bone metastasis in patients
with early-stage breast cancer. Clinical trials are investigating the effect of
zoledronic acid on disease progression in patients with breast cancer, prostate
cancer, and non-small cell lung cancer. The results of these clinical trials
should further define the clinical benefit of bisphosphonates in the oncology
setting.PMID: 15459428 [PubMed - in process]
--------------------------------------------------------------------------
------Who loves ya.
Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://pages.ivillage.com/ironjustice/manisaherbivore
DEAD PEOPLE WALKING http://pages.ivillage.com/ironjustice/deadpeoplewalking